AstraZeneca to file lesinurad on combo data
This article was originally published in Scrip
Executive Summary
AstraZeneca's selective uric acid re-absorption inhibitor (SURI) lesinurad has achieved enough success in three pivotal studies when used in combination with other gout treatments to warrant approval applications, the company says.